Seroconversion after anti‐SARS‐CoV ‐2 mRNA vaccinations among moderate‐to‐severe psoriatic patients receiving systemic biologicals—Prospective observational cohort study

Abstract

It is unclear whether biological antipsoriatic therapies affect seroconversion after messenger ribonucleic acid (mRNA)‐based antisevere acute respiratory syndrome coronavirus 2 (anti‐SARS‐CoV‐2) vaccinations. To assess antibody formation and the incidence of side effects after anti‐SARS‐CoV‐2 mRNA vaccinations in psoriatic patients receiving different biologicals compared to healthy controls. 102 moderate‐to‐severe psoriatic patients (56.2 [±13.5] years) and 55 age‐matched healthy (56.4 ± 13.6 years) volunteers were included in our study. Ten to 21 days after the administration of the second dosage of BNT162b2 or mRNA‐1273 vaccine, antibody levels specific to the SARS‐CoV‐2 spike (S) protein receptor binding domain were monitored. The incidence of postvaccination side effects was recorded and compared to real‐life data in the literature. Of the 102 patients, 57 (55.88%) received tumor necrosis factor (TNF), 28 (27.45%) received interleukin (IL)‐12/23, 16 (15.68%) received IL‐17, and 1 (0.99%) received IL‐23 inhibitors. No significant differences in the median serum level of anti‐SARS‐CoV‐2S antibody were observed between the study population and the control group (median IQR range: 1681.0 U/mL (600.0–4844.0) versus 1984.0 U/mL (1000.0–3136.0; p = 0.82). The most frequent side effects of the mRNA vaccines within 7 days after the administration of both dosages were arm pain on the side of injection (23.53% and 23.53%), fatigue (9.80% and 13.72%), headache (4.9% and 5.88%), and chills or shivering (4.9% and 8.82%). Detectable antibodies against SARS‐CoV‐2S protein appear 10–21 days after the administration of the second dosage of BNT162b2 or mRNA‐1273 vaccines in moderate‐to‐severe psoriatic patients receiving biologicals, similar to those of healthy controls.

COVID-19 vaccination in psoriasis patients receiving systemic treatment: A prospective single-center study

“…The authors reported that all patients showed seroconversion after completed vaccination consisting of two doses, which fits in well with our findings (44,49). Other studies also presented similar findings (50)(51)(52)(53)(54)(55)(56). The main results of other studies that also investigated the serological response to COVID-19 vaccination in psoriasis patients are summarized in Table 4 Two of three patients without seroconversion received MTX.…”

Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines among Patients with Immune-Mediated Dermatological Diseases: A Systematic Review and Meta-analysis

“…Furthermore, immunosuppressed patients had a lower incidence of AEs. Previous studies on IMDD patients' humoral immune responses in psoriasis, AIBD, and CSU patients showed no statistically significant differences from HCs (27,(32)(33)(34)(35)(36)(37). By stratifying participants of the IMDD group into individual diseases, Chanprapaph et al demonstrated that AIBD patients exhibit poor immune responses, whereas psoriasis patients develop comparable post-vaccination immune responses to a healthy population (32).…”

Seroconversion and neutralizing antibodies production after completion of Pfizer‐BioNTech BNT 162b2 vaccination scheme among psoriatic patients receiving biological or topical treatment: A prospective observational cohort study

“…1 In order to evaluate the efficacy of vaccination on psoriatic patients receiving drugs potentially affecting immune system response, some studies have been performed. [2][3][4][5][6][7][8] However, such analyses only compared psoriatic patients with healthy controls. The aim of our study was to assess the rate of anti-SARS-CoV-2 neutralizing antibodies in psoriatic patients under topical and biological therapies after the completion of the first vaccination cycle with BNT162b2 vaccine and to verify whether there could be a difference between the different type of treatments.…”